|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.53 USD | -0.10% |
|
+7.50% | +6.29% |
| 12/05 | Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley | MT |
| 12/05 | Morgan Stanley Cuts Price Target on Halozyme Therapeutics to $93 From $96, Keeps Overweight Rating | MT |
| Capitalization | 848.44Cr 734.75Cr 674.18Cr 634.29Cr 1.18TCr 81TCr 1.2TCr 8.01TCr 3.12TCr 39TCr 3.19TCr 3.12TCr 1,36000Cr | P/E ratio 2026 * |
10.6x | P/E ratio 2027 * | 8.19x |
|---|---|---|---|---|---|
| Enterprise value | 970.22Cr 840.21Cr 770.95Cr 725.34Cr 1.35TCr 92TCr 1.37TCr 9.16TCr 3.57TCr 45TCr 3.64TCr 3.56TCr 1,55500Cr | EV / Sales 2026 * |
5.46x | EV / Sales 2027 * | 4.27x |
| Free-Float |
98.94% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Halozyme Therapeutics, Inc.
| 1 day | -0.10% | ||
| 1 week | +7.50% | ||
| Current month | +7.50% | ||
| 1 month | +7.81% | ||
| 3 months | +6.17% | ||
| 6 months | +12.95% | ||
| Current year | +6.29% |
| 1 week | 65.6 |  | 72.25 |
| 1 month | 63.5 | | 73.89 |
| Current year | 61.32 | | 82.22 |
| 1 year | 51.06 | | 82.22 |
| 3 years | 32.78 | | 82.22 |
| 5 years | 29.85 | | 82.22 |
| 10 years | 7.7 | | 82.22 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 63 | 06/01/2014 |
David Ramsay
DFI | Director of Finance/CFO | 61 | 01/05/2013 |
Charles Theuer
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Matthew Posard
BRD | Director/Board Member | 58 | 28/03/2013 |
Helen Torley
BRD | Director/Board Member | 63 | 06/01/2014 |
| Chairman | 61 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 03/06 | Fiscal year | Chief Executive Officer | 30,000 | 0.0253% | ||
| 01/06 | Sell | Director | -1,625 | 0.0014% | ||
| 13/05 | Fiscal year | Chief Executive Officer | 30,000 | 0.0253% |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.10% | +7.50% | +31.85% | +110.51% | 848.44Cr | |
| -1.90% | +4.59% | +18.79% | -19.74% | 6.87TCr | |
| -0.46% | -8.62% | -5.96% | -16.97% | 747.68Cr | |
| -2.65% | -1.78% | -2.54% | +18.57% | 443.49Cr | |
| -3.25% | -8.82% | -25.34% | +33.62% | 371.67Cr | |
| +1.66% | -7.21% | -21.79% | -8.15% | 303.59Cr | |
| +0.11% | -3.10% | +34.99% | +29.37% | 259.73Cr | |
| +0.71% | -3.88% | -1.20% | -19.16% | 194.91Cr | |
| +1.01% | -3.45% | -16.65% | -21.75% | 177.39Cr | |
| -0.82% | -5.89% | +11.57% | +18.29% | 167.06Cr | |
| Average | -0.57% | -2.90% | +2.37% | +12.46% | 1.04TCr | |
| Weighted average by Cap. | -1.46% | +2.18% | +13.71% | -3.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 177.69Cr 153.88Cr 141.19Cr 132.84Cr 247.41Cr 17TCr 251.28Cr 1.68TCr 653.14Cr 8.19TCr 667.17Cr 652.65Cr 28TCr | 199.88Cr 173.1Cr 158.83Cr 149.43Cr 278.32Cr 19TCr 282.67Cr 1.89TCr 734.73Cr 9.21TCr 750.51Cr 734.18Cr 32TCr |
| Net income | 82Cr 71Cr 65Cr 61Cr 114.38Cr 7.83TCr 116.17Cr 775.88Cr 301.96Cr 3.79TCr 308.45Cr 301.73Cr 13TCr | 104.45Cr 90Cr 83Cr 78Cr 145.44Cr 9.95TCr 147.71Cr 986.51Cr 383.94Cr 4.81TCr 392.18Cr 383.65Cr 17TCr |
| Net Debt | 121.79Cr 105.47Cr 97Cr 91Cr 169.58Cr 12TCr 172.23Cr 1.15TCr 447.66Cr 5.61TCr 457.28Cr 447.33Cr 20TCr | 5.36Cr 4.64Cr 4.26Cr 4.01Cr 7.46Cr 510.6Cr 7.58Cr 51Cr 20Cr 246.93Cr 20Cr 20Cr 858.72Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/26/05 | 71.53 $ | -0.10% | 11,44,601 |
| 04/26/04 | 71.60 $ | +2.55% | 22,54,282 |
| 03/26/03 | 69.82 $ | +5.34% | 21,44,788 |
| 02/26/02 | 66.28 $ | -2.73% | 17,41,056 |
| 01/26/01 | 68.14 $ | +2.40% | 23,87,416 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HALO Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition